Responses
Immunotherapy biomarkers
Original research
Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial
Compose a Response to This Article
Other responses
No responses have been published for this article.